August 26th, 2013
What is the impact of the larger than usual amount of missing data in the ATLAS ACS 2-TIMI 51? A member of the FDA’s Cardiovascular and Renal Drugs Advisory panel answers questions about this issue.
January 3rd, 2012
There is a problem so grave that it threatens the very validity of what we learn from the medical literature. Bad data? Not exactly. Actually, it’s missing data — information, relevant to the risks and benefits of treatments, that is simply not published. In some cases, these data would make a critical difference in the […]